October 17, 2026 06:02 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Internet access a fundamental right for children': SC rejects age-based 'blanket' ban | 'We will fight our own government': RG Kar victim's father threatens fresh protest after Sandip Ghosh gets bail | RG Kar shocker: Sandip Ghosh gets bail as only 7 of 147 witnesses examined, junior doctor blasts CBI | Trump waives Russia-related sanctions | 'How dare Elon Musk?' Owaisi defends Modi after billionaire's 'real boss' jibe at Ambani | 'B****y S***': IAS officer's abuse of female colleague during virtual J&K meeting sparks row | Aamir Khan’s nephew Imran Khan asked to leave India by Oct 28 after joining anti-CEC protest | ‘Their crime? Demanding justice’: Rahul Gandhi slams 4 AM detention of Ankita Bhandari’s parents | ‘Bangladesh showed us the way’: Neha Bora’s remarks spark BJP attack on Rahul Gandhi | Chingrighata flyover skid scare: Bikes fall, anti-skid blocks installed overnight as Bengal Minister Agnimitra Paul faces criticism
ZyCoVD
Image Credit: Pixabay

Zydus Cadila seeks DCGI's emergency use approval for its 3-dose, 'needle free' vaccine : Reports

| @indiablooms | Jul 01, 2021, at 09:13 pm

New Delhi/IBNS: Gujarat-based pharma company Zydus Cadila has sought Drugs Controller General of India's (DCGI) approval for emergency use of its ZyCoV-D three-dose Covid shot which is the "world's first Plasmid DNA vaccine" and safe for children above the age of 12, according to media reports.

According to Reuters, the company has provided the interim results from phase III clinical trials that involved over 28,000 volunteers, across the country, including about 1,000 subjects in the 12-18 year age group, Zydus says.

The study was carried out "during the peak of the second wave of COVID-19 (in India), reaffirming the vaccine's efficacy against the new mutant strains, especially the Delta variant," Zydus said in a statement to the stock exchanges, according to Reuters.

The company claims 66.6 per cent efficacy of the vaccine against symptomatic Covid cases and 100 per cent for moderate infections.

The vaccine was found to be safe for children between 12 and 18 years but its trial data is awaiting peer-review.

The vaccine is ideally stored at 2 to 8 degree Celsius but has shown good stability at temperatures of 25degrees for at least three months, says the company, easing difficulties faced in transporting and storing coronavirus vaccines and also reduces any cold chain breakdown challenges.

"Also, being a plasmid DNA vaccine, ZyCoV-D doesn't have any problem associated with vector based immunity," the company says in a statement.

A plasmid DNA vaccine works by producing the spike protein of the coronavirus and subsequently inciting an immune response, Zydus says, adding thatifications can be made to the plasmid DNA platforms to deal with new mutations.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.